News

As part of this collaboration, PPD will be providing Merck with assay development and immunogenicity testing services to support Merck’s vaccine portfolio over a period of five years.

Dr Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside. Co-founder of ProlX Pharmaceuticals, Dr Kirkpatrick

This new center has 24 treatment stations and is currently caring for approximately 145 dialysis patients. The company is considering adding six more stations to the facility, which

Prism intends to submit a supplemental new drug application (NDA) for the premixed configurations which will form the focus of the commercial launch of Nexterone as a complete

Mr Elstein has been a member of Teva’s senior management since 2005. Mr Elstein most recently held the position of executive vice president of global pharmaceutical resources. Prior

Prior to joining Oni BioPharma, Dr Handfield was a tenured faculty member at the Center for Molecular Microbiology and Department of Oral Biology, University of Florida. Martin has

“We are delighted and grateful to have the continuing support of GCIC,” said Jake Orville, president and chief executive of Prognostix. “GCIC’s first grant enabled Prognostix to make

The process has also included a review of the potential out-licensing of assets, asset divestiture, or liquidation of the company. Vasogen also reported that during this process it

Year-to-date net income for the first six months of Neogen’s 2009 fiscal year increased 22% to $7,634,000 from $6,265,000 in FY 2008, or to $0.51 per share in